Practical Management of Patients With Relapsed/Refractory Multiple Myeloma Receiving Talquetamab, a GPRC5DxCD3 Bispecific Antibody: Experience in MonumenTAL-1

home / between-the-lines / practical-management-of-patients-with-relapsed-refractory-multiple-myeloma-receiving-talquetamab

A panel of experts on multiple myeloma review data from the MonumenTAL-1 clinical trial investigating talquetamab and provide comprehensive insights on treating patients and managing adverse effects.

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

EP. 1: How Are Patients with Multiple Myeloma (MM) Diagnosed and Staged?

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 5th 2023

A nurse practitioner and two hematologic oncologists outline diagnosis and staging practices for patients with multiple myeloma.

Saad Usmani, MD, MBA, FACP, an expert on multiple myeloma

EP. 2: Overview of Relapsed/Refractory Multiple Myeloma

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 5th 2023

The expert panel provides an overview of relapsed/refractory multiple myeloma, with a focus on current therapeutic options and unmet needs in the treatment space.

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

EP. 3: MonumenTAL-1: Talquetamab in Relapsed/Refractory MM

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 12th 2023

Donna Catamero, ANP-BC, OCN, CCRC, reviews findings from the MonumenTAL-1 study and the panel provides its impressions of the results.

Saad Usmani, MD, MBA, FACP, an expert on multiple myeloma

EP. 4: Talquetamab Safety Profile in Relapsed/Refractory MM

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 12th 2023

The panel discusses the safety profile of talquetamab for patients with relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD, an expert on multiple myeloma

EP. 5: Clinical Strategies for Adverse Event Management in Patients With Multiple Myeloma Receiving Talquetamab

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 19th 2023

Comprehensive insights on the clinical management of adverse events from talquetamab seen in patients with multiple myeloma, including cytokine release syndrome and infections.

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

EP. 6: GPRC5D-Related Oral Adverse Events in Multiple Myeloma

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 19th 2023

A panel of experts on multiple myeloma reviews GPRC5D-related oral toxicities seen in patients receiving treatment.

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

EP. 7: MonumenTAL-1: Proactive Management of Oral Toxicities

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 26th 2023

Following a review of oral adverse events, the expert panel discusses how to manage oral toxicities seen in patients with multiple myeloma who are treated with talquetamab.

Cesar Rodriguez, MD, an expert on multiple myeloma

EP. 8: Multiple Myeloma: Educating Patients on Oral Toxicity Management

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
December 26th 2023

Multiple myeloma specialists discuss patient education approaches regarding the management of oral toxicity stemming from talquetamab treatment and outline potential research approaches.

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

EP. 9: Approaches for Managing Dermatologic Adverse Events from Talquetamab in Multiple Myeloma

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
January 2nd 2024

A panel of experts on multiple myeloma discuss dermatologic adverse effects seen in patients receiving talquetamab, including nail toxicities.

Donna Catamero, ANP-BC, OCN, CCRC, an expert on multiple myeloma

EP. 10: Conclusions from MonumenTAL-1 Study in Multiple Myeloma

Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez, MD;Saad Z. Usmani, MD, MBA, FACP
January 2nd 2024

Following a review of MonumenTAL-1, experts on multiple myeloma discuss the conclusions from the clinical trial and provide their impressions of the findings.